Symbiotic-GYN-18 | NCT07578649

An Interventional Phase 3, Open Label, Randomized Study To Evaluate Efficacy And Safety of PF-08634404 in Combination With Chemotherapy Versus Pembrolizumab in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent Mismatch Repair (MMR) Proficient Endometrial Cancer. Contact: [...]

Symbiotic-GYN-18 | NCT075786492026-06-24T22:28:02+10:00

DESTINY-Ovarian01 | NCT06819007

A Phase 3, Open-label, Multicenter, Randomized Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing, Homologous-Recombination Deficiency Negative Ovarian Cancer. Contact: DESTINY-Ov01@anzgog.org.au

DESTINY-Ovarian01 | NCT068190072026-06-24T21:48:16+10:00

FRAmework-01 | NCT07213804

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer. Contact: FRAMEWORK-01@anzgog.org.au

FRAmework-01 | NCT072138042026-06-24T21:43:38+10:00

RAINFOL-07 | NCT07564141

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator’s Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer. Contact: RAINFOL-07@anzgog.org.au

RAINFOL-07 | NCT075641412026-06-24T21:41:05+10:00

RAINFOL-04 | NCT07225270

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy. Contact: RAINFOL-04@anzgog.org.au

RAINFOL-04 | NCT072252702026-06-24T21:37:42+10:00
Go to Top